Sugi Predict

Sugi Predict / Compounds / SCHEMBL762283

SCHEMBL762283

SCHEMBL762283

Cc1cccc2nsnc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.57
▸ HSD17B10 Q99714 4/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 6/20 0.49
▸ POLB P06746 1/20 0.49
▸ TXNRD1 Q16881 1/20 0.48
▸ TXNRD3 Q86VQ6 1/20 0.48
▸ TXNRD2 Q9NNW7 1/20 0.48
▸ HPGD P15428 3/20 0.47
▸ PTK2B Q14289 1/20 0.47
▸ GAA P10253 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ TP53 P04637 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.44
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198065 0.76 MAPT (0.61) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL178958 0.75 MAPT (0.54) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL13892234 0.73 MAPT (0.41) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL432155 0.73 MAPT (0.57) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL3632810 0.73 MAPT (0.57) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL1821199 0.73 MAPT (0.57) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL10843606 0.73 KDM4E (0.57) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL8747098 0.73 MAPT (0.64) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL1172929 0.73 MAPT (0.57) MAPTHSD17B10KDM4EHIF1AMEN1
SCHEMBL396206 0.73 MAPT (1.00) MAPTHSD17B10KDM4EHIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4493546-B1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2026-05-06 — — EP disclosed
EP-4493546-A1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2025-01-22 — — EP disclosed
CN-119278197-A Imidazole derivatives as potassium channel inhibitors 阿塞西翁制药公司 2025-01-07 — — CN disclosed
US-12030856-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-07-09 — — US disclosed
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 — — US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 — — CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 — — EP disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 — — WO disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
US-20040077605-A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2004-04-22 — — US disclosed
WO-2003062241-A1 FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-31 — — WO disclosed
WO-2003055478-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-10 — — WO disclosed
US-6376664-B1 DETECTORS, CATALYST THE OHIO STATE UNIVERSITY 2002-04-23 — — US disclosed
EP-0946533-A1 PROCESS FOR PREPARING 2,1,3-BENZOTHIADIAZOLES BAYER AG (DE) 1999-10-06 — — EP disclosed
WO-1998027076-A1 PROCESS FOR PREPARING 2,1,3-BENZOTHIADIAZOLES BAYER AKTIENGESELLSCHAFT (DE) 1998-06-25 — — WO disclosed
WO-1998025888-A1 PROCESS FOR PREPARING ISOCYANATES FROM PRIMARY AMINES WHICH ARE NOT READILY DISSOLVED BAYER AKTIENGESELLSCHAFT (DE) 1998-06-18 — — WO disclosed
US-5700807-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1997-12-23 — — US disclosed
EP-0755934-A1 Endothelin receptor antagonists MERCK PATENT GmbH (DE) 1997-01-29 — — EP disclosed
US-4585472-A PRE- AND POSTEMERGENCE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1986-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077605-A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function NCOA1, NCOA3, NR5A2 MAPT 4141/4885HSD17B10 234/4885KDM4E 942/4885
US-12030856-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 MAPT 1789/4885HSD17B10 1699/4885KDM4E 1829/4885
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 MAPT 1789/4885HSD17B10 1699/4885KDM4E 1829/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 MAPT 2025/4885HSD17B10 1632/4885KDM4E 1291/4885
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 MAPT 2025/4885HSD17B10 1632/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.